

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

04 AUG 11 PM 1:17

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Novo Nordisk Pharmaceuticals, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 2401 Pennsylvania Ave., NW, Ste. 300, Washington, DC 20037			
3. Principal Place of Business (if different from line 2) Princeton, NJ 08540 City: _____ State/zip (or Country) _____			
4. Contact Name Michael Mawby	Telephone (202) 663-7851	E-mail (optional) mmby@novonordisk.com	5. Senate ID # 284790-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 36903000

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-Dec)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇌ Termination Date _____

11. No Lobbyin

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇌ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this report period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇌ \$ <u>20,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate ex accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definiti</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e Internal Revenue Code</p>
---	--

Signature Michael Mawby Date -----

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2 (REV. 4/03)

PAGE 1 c

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Increase funding for Nat'l Diabetes Detection Initiative and Nat'l Diabetes Education program as well as appropriations for HHS diabetes related activities.

17. House(s) of Congress and Federal agencies contacted Check if None

House and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Peter Norman	Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Michael Mawby Date 8/10/04

Printed Name and Title Michael Mowbray, Chief Government Affairs Officer

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each coc information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Passage HR 1581, United states Patent and Trademark Fee Modernization Act of 2003

17. House(s) of Congress and Federal agencies contacted Check if None

House and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Peter Norman	Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Michael Mawby Date 8/10/2004

Printed Name and Title Michael Mawby, Chief Govt Affairs Officer

Form LD-2 (Rec. 4/03)

Page 3

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Increase Congress' awareness of diabetes and the dangers of importation; S. 1666, Diabetes Prevention and Treatment Act of 2003; HR 1916, Diabetes Prevention Access and Care Act; HR 3194 Diabetes self Management Training Act of 2003

17. House(s) of Congress and Federal agencies contacted Check if None

House and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Peter Norman	Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Michael Mawby* Date 8/10/04

Printed Name and Title Michael Mowby, Chief Gvt Affairs Office

Form LD-2 (Rec. 4/03)

Page 4

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Regulations related to each of the diabetes provisions of the Medicare Modernization Act of 2003 to reflect Congress' intent to cover insulin delivery devices

17. House(s) of Congress and Federal agencies contacted Check if None

House and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Peter Norman	Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Michael Mawby Date 8/10/04

Printed Name and Title Michael Marby, Christ Court Affairs Office

Form LD-2 (Rev. 4/03)

Page 5

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Passage of the R&D Tax Credit

17. House(s) of Congress and Federal agencies contacted Check if None

House and Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Peter Norman	Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Michael Mawby Date 8/10/04

Printed Name and Title Michael Mawby, Chief Port Affairs Office

Form LD-2 (Rev. 4/03)

Page 6

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name _____

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bu (city and state or cot

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
Novo Nordisk A/S	Novo Alle	2880 Bagsvaerd Denmark	\$0.00

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, affiliated organization

Signature

Mohal Kaly

Date

8/10/2004

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

Form LD-2 (Rev. 4/03)

Page _____